We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
Expert Review of Anticancer Therapy 2009 June
The recent introduction of drugs that inhibit angiogenesis or the mTOR has provided new options for the treatment of metastatic renal cell carcinoma, a disease which often has a poor prognosis. Chemotherapy and cytokine therapy are largely ineffective. The 5-year survival rate is under 10%. Everolimus, an immunosuppressive drug widely used for the prevention of allograft rejection and an mTOR inhibitor, is one of the latest drugs undergoing clinical trials in metastatic renal cell carcinoma. It has been tested in patients with progressive disease after therapy with tyrosine kinase receptor inhibitors (sunitinib, sorafenib or both), which interfere with signaling pathways, such as the VEGF pathway. Clinical efficacy results (progression-free survival) for everolimus are promising and the safety profile is good.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app